19Sep

LEAP-005 Results at ESMO 2020

Abstract No : Abstract #LBA41

Indication : Gastric Cancer, Colorectal Cancer, Biliary tract cancer, Glioblastoma, Ovarian Cancer, Breast cancer

Intervention : Lenvatinib

Company : Merck & Co.

Technology : multiTKI


Results:

187 pts have been enrolled in LEAP-005. Median study follow-up at Apr 10, 2020 data cutoff was 8.6 (range, 1.9‒13.1) mo. Encouraging efficacy was observed across cohorts, and toxicity was manageable


Conclusion:

187 pts have been enrolled in LEAP-005. Median study follow-up at Apr 10, 2020 data cutoff was 8.6 (range, 1.9‒13.1) mo. Encouraging efficacy was observed across cohorts, and toxicity was manageable